Clinical trials: Infiltrating Cervical Carcinoma
HNSCC, Melanoma
Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors
The subject of this study is the adoptive transfer of selected autologous tumor infiltrating lymphocytes (TIL) after in vitro expansion for the treatment of solid tumor malignancies.
- Conditions
- HNSCC, Melanoma, Gynecologic Cancer, Colorectal Cancer
- Trial name
- ACT (NCT05902520)
- Testing
- DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- AgonOx, Inc.
Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL [LN-144/LN-145 (lifileucel)] in combination with immune checkpoint inhibitors or TIL…
- Conditions
- Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
- Trial name
- NCT03645928
- Testing
- Lifileucel, LN-145, Pembrolizumab
- Where
- 34 sites in United States, Canada and 5 more
- Volunteers
- 225 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Adult, Gynecological Tumors
Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (Advanced Cervical Cancer)
This study is an early exploration clinical study with one arm. The study consists of two stages, namely the dose escalation stage and the dose extension stage:
- Trial name
- NCT06191900
- Testing
- Autologous tumor infiltrating lymphocyte injection（GT201）
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Grit Biotechnology
Solid Tumor, Adult, Cervical Cancer
Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors
This is an open-labeled, single-armed and prospective study, patients with advanced malignant solid tumors will be given with SL22P autologous CAR - T/CAR-TILs cells.
- Conditions
- Solid Tumor, Adult, Cervical Cancer, Sarcoma, NSCLC
- Trial name
- NCT04556669
- Testing
- Autologous aPD-L1 armored anti-CD22 CAR T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Nasopharyngeal Neoplasms
Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
The purpose of this study is to evaluate the safety and efficacy of CC-486 in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma having failed one to two previous regimens, including…
- Trial name
- NCT02269943
- Testing
- CC-486
- Where
- 25 sites in United States, Canada and 7 more
- Volunteers
- 36 people
- Sponsor
- Celgene
Infections, Papillomavirus, Cervical Cancer
Type Distribution of Human Papillomavirus in Adult African Women Diagnosed With Invasive Cervical Cancer
The aim of the study is to assess the distribution of the most frequent types of human papillomavirus in African women diagnosed with invasive cervical cancer.
- Trial name
- NCT01207999
- Testing
- Collection of cervical cancer tissue samples, Data collection
- Where
- 5 sites in Ghana, Nigeria and 1 more
- Volunteers
- 591 people
- Sponsor
- GlaxoSmithKline
Neoplasms, Uterine Cervix, Cervical Cancer
Cross-sectional Study on Human Papillomavirus Type Distribution in Adult Women Diagnosed With Cervical Cancer
The current study will elucidate the human papillomavirus type distribution in a population of women diagnosed with cervical high grade pre-cancerous lesions and invasive cervical cancer in Sri Lanka.
- Trial name
- NCT01221987
- Testing
- Cervical sampling, Data collection
- Volunteers
- 40 people
- Sponsor
- GlaxoSmithKline
Cervical Carcinoma
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
Prospective, multicenter, multiple cohort, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145), with or without pembrolizumab, followed by…
- Trial name
- NCT03108495
- Testing
- LN-145, LN-145 + pembrolizumab
- Where
- 43 sites in United States, France and 6 more
- Volunteers
- 210 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Cervical Cancer, Precancerous Condition
Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer form forming, growing, or coming back. Vaccines may help the body build an effective immune response against human papillomavirus and may be effective in…
- Trial name
- NCT00128661
- Testing
- human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine, hepatitis A inactivated virus vaccine
- Where
- Costa Rica
- Volunteers
- 7,466 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Cancer, Head and Neck Squamous Cell Carcinoma
ITIL-168 in Advanced Solid Tumors
DELTA-2 is a phase 1 clinical trial to evaluate the safety, feasibility, and preliminary efficacy of ITIL-168 with pembrolizumab in participants with advanced cancer whose disease has progressed after standard therapy.
- Conditions
- Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- DELTA-2 (NCT05393635)
- Testing
- ITIL-168
- Sponsor
- Instil Bio
Platinum-resistant Ovarian Cancer, Endometrial Cancer
A Study of DeTIL-0255 in Adults With Advanced Malignancies
This is a first-in-human Phase 1 multicenter, open-label oncology study designed to evaluate the safety and efficacy of NX-DeTIL-0255-201 in patients with advanced malignancies.
- Conditions
- Platinum-resistant Ovarian Cancer, Endometrial Cancer, Cervical Cancer
- Trial name
- NCT05107739
- Testing
- Drug Product De-TIL-0255
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Nurix Therapeutics, Inc.
Adult
Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer
This is a Phase II, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of Autologous Tumor Infiltrating Lymphocytes (GT101 injection) compared with Gemcitabine in participants…
- Trial name
- NCT06241781
- Testing
- GT101 injection, Gemcitabine injection
- Where
- 24 sites in China
- Volunteers
- 83 people
- Sponsor
- Grit Biotechnology
Breast Cancer, Colorectal Cancer
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
A multicenter trial to investigate TBio-4101, an autologous, neoantigen-selected, tumor-reactive TIL product, in patients with advanced solid malignancies.
- Conditions
- Breast Cancer, Colorectal Cancer, Uveal Melanoma, Cutaneous Melanoma
- Trial name
- STARLING (NCT05576077)
- Testing
- TBio-4101, Pembrolizumab
- Where
- 13 sites in United States, Canada
- Volunteers
- 31 people
- Sponsor
- Turnstone Biologics, Corp.
Cervical Cancer
Human Papillomavirus (HPV) Type Distribution in Adult Women Diagnosed With Invasive Cervical Cancer in New Zealand
The aim of this study is to assess the distribution of the most frequent types of human papillomavirus in women diagnosed with invasive cervical cancer in New Zealand.
- Trial name
- NCT01328028
- Testing
- Testing of archived cervical cancer tissue samples, Data collection
- Volunteers
- 244 people
- Sponsor
- GlaxoSmithKline
Squamous Cell Carcinoma of the Head and Neck
Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck
Multicenter, multicohort, non-randomized, prospective, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145/LN-145-S1) followed by IL-2…
- Trial name
- NCT03083873
- Testing
- LN-145, LN-145-S1
- Where
- 22 sites in United States
- Volunteers
- 64 people
- Sponsor
- Iovance Biotherapeutics, Inc.
HNSCC
Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors
This study is a single-arm early exploratory clinical study. designed to evaluate the safety and tolerability of GT201 in combination with a PD-1 inhibitor for the treatment of advanced head and neck tumor subjects with safety…
- Trial name
- NCT06190275
- Testing
- GT201 in combination with PD-1 inhibitors
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Grit Biotechnology
Advanced Solid Tumors, Non-Small Cell Lung Cancer
A Study of IOV-5001 in Adults With Advanced Solid Tumors
A Phase 1/2, multicenter, multi-cohort, open-label study of an autologous tumor-infiltrating lymphocytes (TIL) regimen with IOV-5001 in participants with previously treated advanced solid tumors
- Conditions
- Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer
- Trial name
- NCT07743723
- Testing
- IOV-5001
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Iovance Biotherapeutics, Inc.